Literature DB >> 1433619

Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology.

W D Steers1, J M Meythaler, C Haworth, D Herrell, T S Park.   

Abstract

A prospective, blinded study was done to examine the effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary function in 10 patients with severe spasticity due to spinal cord pathology. Genitourinary function was assessed by symptom questionnaires and urodynamic studies performed after a bolus dose of baclofen and 6 to 12 months after continuous intrathecal baclofen. Results were compared to placebo for acute bolus testing or to pre-continuous intrathecal baclofen values. In all patients with irritative voiding and urge incontinence uninhibited bladder contractions were eliminated. Of 3 patients with an indwelling urethral catheter for incontinence due to detrusor hyperreflexia 1 was converted to intermittent self-catheterization. Whereas bladder capacity, compliance, sensation and voiding pressures were not different after continuous intrathecal baclofen, when a mean of all patients was compiled, a 72% increase in capacity and 16% improvement in compliance were observed in subjects without cervical spinal cord pathology. Detrusor-sphincter dyssynergia was abolished in 40% of the patients. Continuous intrathecal baclofen may represent a novel approach to the management of patients with a neurogenic bladder who have decreased bladder compliance and detrusor hyperreflexia not controlled by oral medications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1433619     DOI: 10.1016/s0022-5347(17)37048-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

Review 1.  CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention.

Authors:  Karl-Erik Andersson; Rikard Pehrson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Neural control of the female urethral and anal rhabdosphincters and pelvic floor muscles.

Authors:  Karl B Thor; William C de Groat
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-19       Impact factor: 3.619

Review 3.  Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences.

Authors:  Emilio Sacco; Francesco Pinto; Pierfrancesco Bassi
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-15

Review 4.  Changes in afferent activity after spinal cord injury.

Authors:  William C de Groat; Naoki Yoshimura
Journal:  Neurourol Urodyn       Date:  2010       Impact factor: 2.696

Review 5.  Neurophysiology of micturition and continence in women.

Authors:  T C Chai; W D Steers
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1997

6.  Roles of Glycinergic and Gamma-aminobutyric-ergic Mechanisms in the Micturition Reflex in Rats.

Authors:  Minoru Miyazato; Naoki Yoshimura; Saori Nishijima; Kimio Sugaya
Journal:  Low Urin Tract Symptoms       Date:  2009-09-01       Impact factor: 1.592

7.  GABA receptor activation in the lumbosacral spinal cord decreases detrusor overactivity in spinal cord injured rats.

Authors:  Minoru Miyazato; Kurumi Sasatomi; Shiro Hiragata; Kimio Sugaya; Michael B Chancellor; William C de Groat; Naoki Yoshimura
Journal:  J Urol       Date:  2008-03       Impact factor: 7.450

Review 8.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Effects of intrathecal baclofen on perceived sexual functioning in men with spinal cord injury.

Authors:  Michael L Jones; Donald P Leslie; Gerald Bilsky; Brock Bowman
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

10.  Intrathecal baclofen: Its effect on symptoms and activities of daily living in severe spasticity due to spinal cord injuries: A pilot study.

Authors:  Yogendrasinh Jagatsinh
Journal:  Indian J Orthop       Date:  2009-01       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.